Introduction {#s3018}
============

The world and health care system is scrambling as COVID-19 pandemic continues to explode [@b0005]. As of 24th March 2020, over 400,000 cases are reported worldwide and the numbers keep rising constantly [@b0005]. Apart from the Artic, it has engulfed every continent and country. With this unimaginable scenario, the healthcare system in the entire world is under immense pressure and struggling to cope.

Available data shows COVID-19 carries high risk or morbidity and mortality for elderly and immuno-compromised individuals [@b0010]. Reports from China show Cancer patients have an aggressive course and carry a 3.5 higher risk of mortality [@b0015]. The study also found patients with cancer deteriorated more rapidly than those without cancer (median time to severe events 13 days vs 43 days) [@b0015].

Cancer centers worldwide are trying to adapt and are struggling with this constantly changing scenario. Hospitals are designing new policy measures and working hard to implement those in place. Radiation Oncology is an integral part of oncology care and the nature of fractionated treatment requires patients to visit cancer centers daily for a significant number of days. The risk of patient contacting/getting exposed to COVID-19 and diffusion of spread is paramount [@b0020]. The risk of decrease in specialized radiation oncology workforce could hamper and even halt operations of radiation oncology centers [@b0025]. Learning from Chinese and Italian experience, aiming to reduce the impact of epidemic operations changes several are recommended [@b0020], [@b0030], [@b0035].

Radiation oncology community must evaluate options of prioritizing radiation treatments (RT), deferring where applicable, omitting where there is no or very minimal benefit and strongly consider reduce numbers of fractions where there is evidence to support [@b0040].

We proposed 4 new R's in the COVID era [@b0005] Vi**R**tual care (reduce in-person consult/follow up/on treatment visits) [@b0010] **R**ation radiation (ofer radiation wisely and avoid RT where minimal benefit) [@b0015] defeR radiation (as appropriate) [@b0020] hypofRactionate radiation (where applicable) and came up with provincial preferred thoracic radiation regimen.

Several measures are adopted by Canadian physicians such as virtual care to minimize in-person clinic visits and deferral where needed. Intending to ensure patient safety and deliver quality care, we sought consensus on the preferred thoracic hypofractionated radiation regimen in our provincial cancer center.

Methods {#s0005}
=======

CancerCare Manitoba provides comprehensive oncology services for the province of Manitoba and adjacent areas of Northwestern Ontario and Nunavut. Approximately 3500 new patients are seen/treated annually including approximately 600--650 new lung cancer patients. We are a modern radiation oncology department with 8 modern linear accelerators including True beam and Edge machines and using IGRT, rapid arc and SRS/SBRT techniques in our standard clinical practice.

With provincial emergency declarations, Thoracic Radiation oncology (RO) group was tasked with disease specific COVID-19 emergency preparedness plan. Our Team reviewed the current evidence to assess the role and available options of different radiation regimens in the management of lung cancers.

We assessed different common scenarios where radiation would be routinely considered and prioritized the indications. Priority levels were assigned based on prognosis and the expected benefit of radiation treatment. Curative treatments, where delay/deferral would jeopardize the survival outcomes, were considered as a high priority. Treatment indications for symptomatic measures or consolidation (treatment gains in quality of life or progression-free survival) were considered as an intermediate priority. Treatment indications where the role of radiation is debatable (no significant overall survival impact or other options as observation were appropriate) were considered as low priority. Thoracic RO team attained consensus and recommended evidence-based preferred hypofractionated radiation regimen for clinical care at our provincial comprehensive cancer center.

Recommendations {#s0010}
===============

Nonsmall cell Lung Cancers:

Stage I-II NSCLC:

Priority level -- high:

RO Consensus: Stage I--II (node negative) NSCLC represents a curative scenario and nonsurgical candidates with good performance status should undergo stereotactic body radiation treatment. Peripheral tumours should be treated with 54 Gy in 3 fractions (FR) and preferred over 48 Gy in 4 Fr option [@b0045], [@b0050]. We do not practice 30--34 Gy in 1 fraction at our center yet, however once available could be preferred for appropriate patients [@b0050]. Central tumours should be treated with 50 Gy in 5 Fr as a preferred option [@b0055]. Group discouraged use of 60 Gy in 8 Fr for central tumours. However, this would be considered a valid option for the treatment of ultra-central tumours. The use of hypofractionated regimen as 60 Gy in 15 Fr is not preferred unless the patient is not a candidate for SBRT [@b0060].

Stage II (node positive) -- III NSCLC:

Priority level -- high:

RO Consensus: Group agreed inoperable stage II (node positive) -- III population with good performance status would be best served with curative concurrent chemo radiation with standard doses of 60 Gy in 30 Fr [@b0065]. Our group did not support concurrent chemo and hypofractionated radiation options. We discouraged the use of a longer regimen such as 66 Gy in 33 Fr at present [@b0065]. We recommended candidates ineligible for concurrent chemo radiation should receive sequential chemoradiation (if suitable) with hypofractionated radiation as 55 Gy in 20 Fr or 40 Gy in 15 Fr.

Stage IV NSCLC:

Priority level -- Intermediate:

RO Consensus: Majority stage IV NSCLC patients face significant symptom burden. Palliative radiation offers a significant improvement in symptoms and Quality of life [@b0070]. Group recommended 8--10 Gy in 1 Fr or 16 Gy in 2 Fr (1 week apart) as preferred regimen over other fractionated regimen as 20 Gy in 5 Fr or 30 Gy in 10 Fr especially in patients with poor performance status [@b0075]. There is no strong evidence that any regimen gives greater palliation [@b0080].

Small-cell Lung Cancers:

Limited stage (stage I--III):

Priority level -- high:

RO Consensus: Concurrent chemo radiation plays a vital role in the management of this curative group of patients. We adopted 40 Gy in 15 Fr as a preferred consensus recommendation for good performance status candidates [@b0085]. Group discouraged use of 45 Gy in 30 Fr BID or 66 Gy in 33 Fr regimens in the current scenario [@b0090], [@b0095]. The evidence suggests early administration of concurrent RT is superior to delayed administration and RO favoured early administration of RT [@b0100].

Stage I SCLC could account for 10% of screen detected lung cancers. Acknowledging the limitations of available data, SBRT should be considered in stage I SCLC [@b0105], [@b0110]. In such cases group favored SBRT should be offered post chemotherapy [@b0115].

Prophylactic cranial radiation:

Priority level -- Intermediate:

RO Consensus: For limited stage SCLC responding to initial therapy, our group supported and recommended standard regimen of PCI (25 Gy in 10 Fr) for eligible patients [@b0120].

Extensive stage (stage III--IV):

Consolidation thoracic radiation:

Priority level -- Intermediate:

RO Consensus: For extensive stage SCLC responding to initial therapy, consolidation thoracic radiation improves progression-free survival; reduces intra-thoracic failures, however, does not improve overall survival significantly. For suitable patients group favored 20 Gy in 5 Fr over other regimens [@b0125], [@b0130].

Prophylactic cranial radiation:

Priority level -- low:

RO Consensus: For extensive stage SCLC responding to initial therapy, the role of PCI is debatable [@b0135], [@b0140]. For eligible patients group supported and recommended MRI surveillance as a preferred option in the current environment [@b0135], [@b0140].

Palliative radiation in SCLC for symptomatic issues:

Priority level -- Intermediate:

RO Consensus: Palliative radiation serves significant improvement in symptoms and Quality of life. The group recommended 8--10 Gy in 1 Fr or 16 Gy in 2 Fr (I week apart) as preferred regimen over other fractionated regimen as 20 Gy in 5 Fr or 30 Gy in 10 Fr.

Summary details of priority and recommended radiation regimen are shown in [Fig. 1](#f0005){ref-type="fig"} and [Table 1](#t0005){ref-type="table"} respectively.Fig. 1Priority pyramid.SBRT -- sterotactic body radiation treatment, RT -- radiation, CT -- chemotherapy, NSCLC -- non small cell lung cancer, SCLC-- small cell lung cancer.Table 1Preferred hypofractionated RT regimen.Preferred fractionated RT regimenPatient visits and RT fractions saved per patient per RT course (with Preferred fractionated RT regimen over other regimens)*Lung NSCLC*SBRT -- Peripheral54 Gy/3 Fr1 FrSBRT -- Central50 Gy/5 Fr3 FrSBRTContinue as usual. You may also wish to assess option of delay for minimally growing tumorsConcurrent CTRT60 Gy/30 Fr3 FrSequential CTRT40 Gy/15 Fr or 50 Gy/20 Fr7--15 FrPall RT lung8--10 Gy/1 Fr4 Fr  *Lung SCLC*Limited stage: Radical40 Gy/15 Fr15 FrLimited stage: PCI25 Gy/10 FrNo changeExtensive stage: consolidation RT (if needed)20 Gy/5 Fr5--10 FrExtensive stage: PCI (if needed)25 Gy/10 Fr (Strongly consider the option of no PCI and MRI regularly)10 Fr (if RT deferred)Pall RT lung8 Gy in 1 Fr4 Fr[^1]

Discussion {#s0015}
==========

With the current pandemic and associated restrictions, we believe this preferred RT regimen will serve as a policy document for the thoracic radiation community ([Table 1](#t0005){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}). The model of vi**R**tual care (reduce in-person consult/follow up/on treatment visits), **R**ation radiation (ofer radiation wisely and avoid RT where minimal benefit), defe**R**  radiation (as appropriate), hypof**R**actionate radiation (where applicable) are emerging as new 4R's of radiation therapy.

These measures will be helpful to minimize patient visits to radiation centers and reduce the risk of patient exposure to infection. The preferred hypofractionated regimen may help minimize the impact of COVID19 on in these unprecedented and unfortunate times. We are hopeful these measures will help mitigate the impact of COVID-19 pandemic on our patients and cancer centers.

Conclusion {#s0020}
==========

In the current times, 4 new R's of Radiation treatment will help mitigate the impact of COVID-19 pandemic on our patients and cancer centers.
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[^1]: Legends: Gy -- Gray, Fr -- fraction, SBRT -- sterotactic body radiation treatment, RT -- radiation, CT -- chemotherapy, NSCLC -- non small cell lung cancer, SCLC -- small cell lung cancer.
